Noah Rosenberg takes chief medical officer role at Esperion

Will develop and manage the firm’s clinical programmes

Noah Rosenberg has taken over as chief medical officer (CMO) at Esperion Therapeutics and will lead the Esperion clinical advisory board and develop and manage the company's clinical programmes. He will also manage the regulatory review process for the company's investigational therapies to treat cardiovascular and metabolic diseases.

Over the past decade, Dr Rosenberg has held senior posts in the pharmaceutical industry, including leadership roles in medical affairs, clinical development and administration in the US and globally at Pfizer, Sanofi and Forest Labs. He has experience working on compounds in all phases of drug development including late stage drugs such as Lipitor and Lantus. Most recently at Forest Research Institute, he led the in-licensing of the GK1-399 programme.

‘Esperion has an established reputation for productivity and success and I look forward to moving novel therapies such as ETC-1002 further along in clinical development,’ Dr Rosenberg said.

You may also like

Research & Development

Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research

Two life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Research & Development

PSI launches platform to speed up site ID, startup and enrolment in pivotal studies

SYNETIC is designed to speed up site identification, startup and patient enrollment in pivotal clinical trials
Ingredients

Piramal Pharma Solutions introduces tablet-in-capsule capabilities

Enhancing dosing flexibility and patient-centric drug delivery
Pharmaceutical

PharmNovo enhances its board ahead of Phase II development

The new board members bring complementary experience in drug development, clinical execution and partnering, supporting the company’s continued progress and dialogue with potential partners
Research & Development

AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic

The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Research & Development

Baseline Therapuetics launches to advance GLP-1 Phase III Programme in Alcohol Use Disorder

The clinical-stage biotech has launched to progress BT-001, a once-weekly GLP-1 receptor agonist, into FDA-aligned Phase III trials for alcohol use disorder, with studies planned to begin in 2026
Research & Development

Researchers identify early signs of Parkinson's in the blood

Researchers at Chalmers University of Technology have identified early-stage Parkinson’s disease biomarkers detectable in blood, revealing a limited diagnostic window that could enable screening and earlier intervention years before motor symptoms appear
Subscribe now